QR Code

Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries

Background: The tyrosine kinase inhibitors (TKIs) asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib have been approved for chronic myelogenous leukemia (CML) therapy. However, pharmacovigilance reports associated with these drugs are neither consistent nor homogenous, with reports...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Ilaria Ammendolia, Carmen Mannucci, Emanuela Esposito, Gioacchino Calapai, Mariaconcetta Currò, Paola Midiri, Cristina Mondello, Antonino Cancellieri, Luigi Cardia, Fabrizio Calapai
Hōputu: Artigo
Reo:Inglês
I whakaputaina: MDPI AG 2026-01-01
Rangatū:Life
Ngā marau:
tyrosine kinase inhibitors
dasatinib
bosutinib
asciminib
imatinib
nilotinib
Urunga tuihono:https://www.mdpi.com/2075-1729/16/1/113
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite